Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma

NCT00454363 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00454363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00454363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
December 31, 2014
Enrollment
52 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastrin-producing neuroendocrine tumor, lung carcinoid tumor, metastatic digestive system neuroendocrine tumor g1, multiple endocrine neoplasia type 1, pancreatic glucagonoma, pancreatic insulinoma, pancreatic polypeptide tumor, recurrent digestive system neuroendocrine tumor g1, recurrent pancreatic neuroendocrine carcinoma, regional digestive system neuroendocrine tumor g1, somatostatin-producing neuroendocrine tumor